SEC Filing Summary: GSK Plc (Form 6-K)
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated June 26, 2026, serves as a notification of a major change in shareholding. The report details an acquisition of voting rights by the investment firm Dodge & Cox, crossing a regulatory threshold on June 23, 2026.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a regulatory disclosure regarding equity ownership.
Material Changes
The material change reported is the increase in Dodge & Cox's total voting rights in GSK Plc:
- Previous Position: 4.93% of voting rights.
- Current Position: 5.01% of voting rights.
- Total Voting Rights Held: 203,320,168 shares.
- Composition: The holding consists entirely of direct voting rights attached to shares (Ordinary shares and ADRs), with 0% held through financial instruments.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or contingencies. It is a standard notification form (TR-1) required under UK Disclosure and Transparency Rules (DTR) and reported to the SEC.
Key Facts for Investor Verification
- Shareholder: Dodge & Cox (San Francisco, USA).
- Threshold Crossed: The 5% voting rights threshold was crossed on June 23, 2026.
- Notification Date: GSK Plc was notified on June 25, 2026.
- Instrument Type: The increase is derived from direct share ownership (Ordinary shares and ADRs), not derivatives or financial instruments.
- Control Status: Dodge & Cox states it is not controlled by any natural person or legal entity and does not control other undertakings holding an interest in the issuer.